Want to see STOK full AI Analyst Report?
STOK Stock Chart & Stats
$33.09
$0.81(2.76%)
At close: 4:00 PM EDT
$33.09
$0.81(2.76%)
Day’s Range― - ―
52-Week Range$20.32 - $40.22
Previous CloseN/A
Volume36.19K
Average Volume (3M)865.93K
Market Cap
$1.60B
Enterprise Value$1.87B
Total Cash (Recent Filing)$292.82M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Nov 10, 2026EPS Estimate
-0.93Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.36
Shares Outstanding64,526,245
10 Day Avg. Volume787,867
30 Day Avg. Volume865,932
Financial Highlights & Ratios
PEG Ratio2.85
Price to Book (P/B)5.33
Price to Sales (P/S)10.19
P/FCF Ratio41.85
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue67.78
Enterprise Value/Gross Profit80.05
Enterprise Value/Ebitda-9.02
Forecast
1Y Price Target
$45.11Price Target Upside36.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-3.64
Revenue Forecast (FY)$32.03M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces financing pressure and preserves flexibility while Stoke funds clinical development. Sizable equity provides support for the asset base, allowing management to pursue regulatory and commercial milestones without the constraints typically created by high leverage.
Phase III ExecutionCompleting enrollment ahead of target and reporting no discontinuations strengthens confidence in execution and study retention. The larger-than-planned cohort and favorable continuation rate support the ability to generate interpretable data for the pivotal readout and regulatory process.
Durable Clinical DataLong-term functional and seizure data provide evidence that zorevunersen’s potential benefit may persist beyond an initial treatment period. Extended follow-up, broad dose experience, and no new safety signals can support clinician confidence and future regulatory and commercial positioning.
Bears Say
Cash Burn And LossesHeavy cash consumption and sharply expanded losses can reduce financial flexibility as Stoke advances several development programs. If the pattern persists, the company may need additional funding before achieving product revenue, increasing execution pressure and the risk of shareholder dilution.
Regulatory UncertaintyUnresolved FDA agreement on the statistical analysis plan creates uncertainty around how pivotal results will be analyzed and presented. Changes to endpoint hierarchy or composite methods could complicate interpretation, regulatory discussions, labeling, and the path from readout to approval.
Extended Approval TimelineThe multi-year period before a pivotal readout and potential launch leaves Stoke exposed to prolonged development and regulatory execution risk. Delays or an unfavorable result could defer revenue generation while the company continues funding clinical, regulatory, and commercial preparation.
Stoke Therapeutics News
STOK FAQ
What was Stoke Therapeutics Inc’s price range in the past 12 months?
Stoke Therapeutics Inc lowest stock price was $20.32 and its highest was $40.22 in the past 12 months.
What is Stoke Therapeutics Inc’s market cap?
Stoke Therapeutics Inc’s market cap is $1.60B.
When is Stoke Therapeutics Inc’s upcoming earnings report date?
Stoke Therapeutics Inc’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were Stoke Therapeutics Inc’s earnings last quarter?
Stoke Therapeutics Inc released its earnings results on Aug 03, 2026. The company reported -$0.93 earnings per share for the quarter, missing the consensus estimate of -$0.795 by -$0.135.
Is Stoke Therapeutics Inc overvalued?
According to Wall Street analysts Stoke Therapeutics Inc’s price is currently Undervalued.
Does Stoke Therapeutics Inc pay dividends?
Stoke Therapeutics Inc does not currently pay dividends.
What is Stoke Therapeutics Inc’s EPS estimate?
Stoke Therapeutics Inc’s EPS estimate is -0.93.
How many shares outstanding does Stoke Therapeutics Inc have?
Stoke Therapeutics Inc has 64,526,245 shares outstanding.
What happened to Stoke Therapeutics Inc’s price movement after its last earnings report?
Stoke Therapeutics Inc reported an EPS of -$0.93 in its last earnings report, missing expectations of -$0.795. Following the earnings report the stock price went up 7.138%.
Which hedge fund is a major shareholder of Stoke Therapeutics Inc?
Currently, no hedge funds are holding shares in STOK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stoke Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.11 (36.33% Upside)
$45.11 (36.33% Upside)
Blogger Sentiment
Bullish
STOK Sentiment 60%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 81.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.97%
12-Months-Change
Fundamentals
Return on Equity
-59.36%
Trailing 12-Months
Asset Growth
2.46%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Stoke Therapeutics Inc
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
STOK Company Deck
STOK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivers multiple strong operational and clinical positives: faster-than-expected Phase III enrollment (162 vs target ≥150), 0% discontinuations (vs 15% assumed), robust long-term OLE data (statistically significant Vineland improvements through 4 years, durable seizure reductions), completed manufacturing validation, and a pro forma cash position (~$420M) supporting runway to a potential early-2028 U.S. launch. Key risks are procedural and timing-related rather than clinical safety: SAP and label details are not yet finalized with the FDA, the final Phase III readout and completion of the rolling NDA extend into Q3 2027, inclusion of OLE data in the label is not guaranteed, and diagnosis/access gaps (particularly in adults) and reliance on partner execution outside North America remain challenges. On balance, the positive clinical progress, regulatory preparedness, financial runway, and commercial planning materially outweigh the remaining uncertainties.View all STOK earnings summariesSTOK Stock 12 Month Forecast
Average Price Target
$45.11
▲(36.33% Upside)
Technical Analysis
Sarepta Therapeutics
―
uniQure
―
Wave Life Sciences
―
Intellia Therapeutics
―
Taysha Gene Therapies
―
Ownership Overview
27.41% Insiders
20.15% Mutual Funds
1.88% Other Institutional Investors
35.34% Public Companies and
Individual Investors